Eric K. Singhi: Decoding clinical trial jargon
Eric K. Singhi, Assistant Professor in the Department of General Oncology at The University of Texas MD Anderson Cancer Center, posted on X about recent paper by him as co-author, titled “Decoding clinical trial jargon: helping people understand the efficacy end points used in cancer trials” published on Taylor and Francis.
Authors: Marty Henley, Gissoo Decotiis, Hannah Fitzgibbon, Eric K. Singhi
“Patients with cancer deserve clear, accessible treatment information to make informed decisions.
Grateful to co-author this patient education publication on decoding clinical trial jargon—featuring visual guides on trial efficacy endpoints.”
Dr. Eric K. Singhi is a thoracic and head and neck medical oncologist, currently serving as an Assistant Professor in the Department of General Oncology within the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center in Houston, TX.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023